Abstract:The discovery of hypoxia-inducible factor-1 has led to a rapidly increasing understanding of the molecular mechanism of tumor hypoxia in the past two decades. Today it is generally accepted that HIF-1 plays a pivotal role in the cellular response to tumor hypoxia which represents a major obstacle to the success of radiotherapy and chemotherapy. Meanwhile, many details involved in the expression, accumulation and transactivation of HIF-1 have been well elucidated. Targeting HIF-1 has become a novel and efficient strategy for cancer therapy and a number of agents have been developed aiming to suppress HIF-1. This review will concisely introduce the general knowledge on the molecular biology of HIF-1 and possible targets along the HIF-1 pathway. Moreover, a number of compounds reported with anti-HIF-1 activity are included and mainly classified as direct and indirect inhibitors based on their different modes of action. While direct HIF-1 inhibitors prevent HIF-1 from transactivation, DNA binding and subsequently initiating transcriptional activity, indirect HIF-1 inhibitors generally block the transcription or translation of HIF-1α or promote the degradation of HIF-1α protein. According to different structural features, direct HIF-1 inhibitors are divided into several groups: polyamides, quinols and naphthoquinone spiroketal analogues, shikonin derivatives, epidithiodiketopiperazines, and two representative drugs: echinomycin and bortezomib. In the same way, indirect inhibitors comprise the following classes: polyphenols, benzoazaheterocycles, rapamycins, camptothecins, geldanamycins, (aryloxyacetylamino)benzoic acid analogues, 2-methoxyestradiol and analogues, hydroxamic acid compounds and others. The rest with mechanism still not so clear would also be listed and introduced, with an emphasis on the marinederived natural products. The in vitro and/or in vivo activities of these compounds and their mechanisms of HIF-1 inhibition would be discussed and the SARs of unique structural types of HIF-1 inhibitors will be briefly concluded.

Advances in antitumor research of HIF-1α inhibitor YC-1 and its derivatives

The Advancement in YC-1 Anti-hepatocellular Carcinoma Mechanisms

Hypoxia Inducible Factor-1 alpha: A New Anticancer Drug Target

Cancer Therapeutic Agents Targeting Hypoxia-Inducible Factor-1

Novel potent HIF-1 inhibitors for the prevention of tumor metastasis: discovery and optimization of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives

Targeting Hypoxia-Inducible Factor-1, for Cancer Treatment: Recent Advances in Developing Small-Molecule Inhibitors from Natural Compounds.

Design, synthesis, and evaluation of novel ursolic acid derivatives as HIF-1α inhibitors with anticancer potential

Anticancer Activity of Natural Flavonoids: Inhibition of HIF-1α Signaling Pathway

YC-1 Inhibits HIF-1 Expression in Prostate Cancer Cells: Contribution of Akt/NF-κB Signaling to HIF-1α Accumulation During Hypoxia

Effects of YC-1 Targeting Hypoxia-Inducible Factor 1 Alpha in Oesophageal Squamous Carcinoma Cell Line Eca109 Cells.

Action Sites and Clinical Application of HIF-1α Inhibitors

Design, Synthesis and Structure-Activity Relationship Studies of Novel 4 (1-Adamantyl) Phenyl Analogues As HIF-1α Inhibitors.

Effects of YC-1 on Hypoxia-Inducible Factor 1-Driven Transcription Activity, Cell Proliferative Vitality, and Apoptosis in Hypoxic Human Pancreatic Cancer Cells

YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole] Inhibits Endothelial Cell Functions Induced by Angiogenic Factors in Vitro and Angiogenesis in Vivo Models.

Recent Agents Targeting Hif-1 Alpha For Cancer Therapy

Targeting Transcription Factor YY1 for Cancer Treatment: Current Strategies and Future Directions

Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents.

Discovery of Novel Aryl Carboxamide Derivatives As Hypoxia-Inducible Factor 1α Signaling Inhibitors with Potent Activities of Anticancer Metastasis.

Advances in the research and development of HIF-1 inhibitors

HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies

Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): A “structure-activity relationship” perspective